All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

Shield Blood Test Yields High Sensitivity, Specificity for CRC Screening in Expansion Cohort of Average-Risk Adults

September 12th 2025

The Shield blood-based CRC screening test demonstrated a sensitivity of 84% for detecting CRC with 90% specificity in an expanded cohort.

Evolving Surgical Strategies and the Role of Mirvetuximab Soravtansine Shape the Ovarian Cancer Treatment Paradigm

September 11th 2025

Ryan M. Kahn, MD, MHS, FACOG, discusses the evolution of surgical techniques and practice-changing treatments in the ovarian cancer treatment paradigm.

Second-Line Axi-Cel and Liso-Cel Lead as Standards of Care in LBCL

September 11th 2025

Supriya Gupta, MD, discussed the utility of axi-cel and liso-cel in real-world settings as second-line treatment in large B-cell lymphoma.

Fox Chase Cancer Center Breast Program Receives Accreditation for Sixth Consecutive Time

September 11th 2025

The NAPBC has renewed Fox Chase Cancer Center’s accreditation, making it the sixth consecutive time Fox Chase has been honored with this distinction.

EMA Validates Marketing Authorization Application for T-DXd in HER2+ Metastatic Solid Tumors

September 11th 2025

The marketing authorization application submitted to the EMA for T-DXd in HER2-positive unresectable or metastatic solid tumors has been validated.

Ateganosine Sequenced With Cemiplimab Displays Activity in Pretreated NSCLC

September 11th 2025

Ateganosine sequenced with cemiplimab was active in advanced NSCLC after disease progression on 2 or more standard therapies.

Experts Highlight Key Topics to Watch at the 22nd International Myeloma Society Annual Meeting

September 11th 2025

Experts preview abstracts being presented at IMS, highlighting the role of MRD, bispecific antibodies, and other strategies to refine myeloma management.

Orelabrutinib Receives Approval in Singapore for Marginal Zone Lymphoma

September 11th 2025

Orelabrutinib has been approved as a treatment option for patients with marginal zone lymphoma in Singapore.

FLAURA-2 and HARMONi Trial Readouts Reinforce Importance of ‘Divide and Conquer’ Approach to Lung Cancer Care at WCLC 2025

September 11th 2025

Experts reflect on pivotal data, emerging agents, and highly anticipated trends in lung cancer during the IASLC 2025 World Conference on Lung Cancer.

From Growing Survivorship Programs to Practicing Self-Care: A Day in the Life With Oncologist Alicia Morgans, MD, MPH

September 10th 2025

Alicia Morgans, MD, MPH, shares her typical work week, the importance of saying yes to career opportunities, and the value of trusted team communication.

Lutetium Lu 177 Dotatate Yields Partial Responses in Metastatic Bronchopulmonary Neuroendocrine Tumors

September 10th 2025

Real-world data showed that lutetium Lu 177 dotatate led to partial responses in patients with metastatic bronchopulmonary neuroendocrine tumors.

Relacorilant NDA Is Under FDA Review for Platinum-Resistant Ovarian Cancer

September 10th 2025

The FDA accepted a NDA for relacorilant in platinum-resistant ovarian cancer based on data from ROSELLA and other phase 2 trials.

FDA Grants Fast Track Designation to GLSI-100 in HLA-A*02+, HER2+ Breast Cancer

September 10th 2025

GLSI-100 received fast track designation from the FDA for patients with HLA-A*02- and HER2-positive breast cancer after SOC therapy.

Roswell Park Leads Largest-Ever Genomic Study of Triple-Negative Breast Cancer in African American Women

September 10th 2025

Findings reveal that cancer genomics similar to other populations, but with some distinctive features.

FDA Approves Selumetinib for Symptomatic Pediatric NF-1–Associated Inoperable Plexiform Neurofibromas

September 10th 2025

The FDA approved selumetinib granules and capsules for the treatment of pediatric patients at least 1 year of age with NF1 and plexiform neurofibromas.

SOHO Spotlight: Hematologists Share Practice-Informing Insights From the 2025 Annual Meeting

September 10th 2025

Hematology experts highlight the MDS, lymphoma, and myeloma data they were most excited to see at the 2025 SOHO Annual Meeting.

Repotrectinib Demonstrates Durable Efficacy in TKI-Naive and -Pretreated ROS1+ NSCLC

September 10th 2025

Repotrectinib elicited durable responses, including intracranial responses, in TKI-naive and -pretreated patients with NSCLC.

Elenestinib May Be Safer Than Traditional KIT Inhibitors in Indolent Systemic Mastocytosis

September 10th 2025

Tsewang Tashi, MD, discusses how elenestinib could be an effective option with a manageable safety profile in ISM.

Cemiplimab Plus Chemotherapy Provides Long-Term Survival Benefit in Advanced NSCLC

September 10th 2025

Five-year data show cemiplimab plus chemotherapy delivers durable OS, ORR, and DOR benefits in advanced NSCLC.

FDA Approves TAR-200 in BCG-Unresponsive NMIBC With CIS

September 9th 2025

The FDA approved TAR-200 in patients with BCG-unresponsive NMIBC with carcinoma in situ, with or without papillary tumors.